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Treatment of hypertension in patients 80 years and older:
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Theodora Bejan-Angoulvant''b'", Mitra Saadatian-Elahi", James M. Wrightd,
Eleanor B. Schronu, Lars H. Lindholmr, Robert Fagards, Jan A. Staessens and
Franqois G ueyffiera'o'c
Background Results of randomized controlled
trials are consistent in showing reduced rates oÍ
stroke, heart failure and cardiovascular events in very old
patients treated with antihypertensive drugs. However,
inconsistencies exist with regard to the effect of these drugs
on total mortality.
Methods We performed a meta-analysis of available data
on hypertensive patients 80 years and older by selecting
total mortality as the main outcome. Secondary outcomes
were coronary events, stroke, cardiovascular events, heart
failure and cause-specific mortality. The common relative
risk (RR) of active treatment versus placebo or no treatment
was assessed using a random-effect model. Linear meta-
regression was performed to explore the relationship
between intensity of antihypertensive therapy and blood
pressure (BP) reduction and the log-transformed value of
total mortality odds ratios (ORs).
Resu/ts The overall RR for total mortality was 1,06 (950/o
confidence interval 0.89-1.25), with signiÍicant
heterogeneity between hypertension in the very elderly trial
(HYVET) and the other trials. This heterogeneity was not
explained by differences in the follow-up duration between
trials. The meta-regression suggested that a reduction in
mortality was achieved in trials with the least BP reductions
and the lowest intensity of therapy, Antihypertensive
therapy significantly reduced (P<0.001) the risk of stroke
(350/0), cardiovascular events (27o/o) and heart failure (500/0),
Cause-specific mortality was not different between treated
and untreated patients.
Introduction
The use of antihypertensive treatment has been shown to
have clear beneficial effects in terms of reducing stroke,
cardiovascular events and mortality in middle-aged and
older patients [1,21. However, until recently, the benefits
of this treatment have not been proven in paticnts over
80 years of age [3-5].
The hypothesis that antihypertensive drugs might be less
efficient and even harmful in very old patients, over
80 years old, was first pointed-out by Amery et al. 16l
more than 20 years ago. The first meta-analysis of sub-
groups of 80 years and older from published papers
reinforced the evidence that treating elderly patients
with antihypertensive drr-rgs reduces the rate of fatal
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and nonfatal stroke [relative risk (RR) 0.66, 95Vo confi-
dence interval (CI) 0.48-0.921, major cardiovascular
events (relative risk 0.78, 9SVoCI 0.64-0.94) and heart
failure (relative risk 0.61, 95%CI0.42-0.88) but leads to a
borderline increase in the overall mortality (relative risk
l.06, 9SVoCl 0.95 
- 
1. 1 8). This subgroup meca-analysis did
not find an impact on other measured outcomes, that is
cardiovascular death and major coronary events [1].
Lack of confidence about the harms and benefits of anti-
hypertension therapy in people civer 80 led to the hyper-
tension in the very elderly trial (HWET). The pilot trial
included three groups in an open label design; no treat-
ment, bendrofluazide (diuretic) and lisinopril (angio-
tensin-converting enzyme inhibitor) [7]. Consistent with
DOI:1 0.1 097/HJH.0b0 1 3e328339Í9c5
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results of the sLrbgroup meta-analysis, the trial found a
significant decrease in fatal and nonfatal strokes with active
treatme nt (relative hazard rate 0.31, 95%CI0.l2-0.79) and
a non-significant increase in total moÍtality (relative hazard
late 1.23,95%C10.75-2.01). This led to an irp-dated 1.15
estimate of the pooled relative risk of death reaching
statistical significance (95% CI 1.01- 1.31) [7].
The results of the main HWET, the largest double-
blind, placebo-controlled trial to date, provided further
evidence on the efficacy of antihypertensive treatment on
fatal and nonfatal stroke (unadjusted hazard ratio 0.70,
9SVoCl 0,49-1.01), cardiovascular events (unadjusted
hazard ratio 0.66, 9SVoCI 0.53-0.82) and heart failure
(unadjusted hazard ratio 0.36, 9SVoCI0.22-0.58). How-
ever, contrary to the earlier trials, HWET found a
statistically significant decrease in the overall mortality
(unadjusted hazard ntio 0.79, 95VoCI0.65-0.95) associ-
ated with antihypertensive treatment [3],
We, therefore, aimed to update the published subgroup
meta-analysis by adding new evidence from randomized
clinical trials (HWET pilot and HWETs) that evaluated
the effect of antihypertensive treatment compared with
placebo or no treatment in patients 80 years and older.
The primary outcome was total mortality. Secondary
outcomes were coronary events, stroke, cardiovascular
events, heart failure and cause specific mortality (coro-
nary, stroke and cardiovascular).
Methods
ldentification of trials
The flow diagram of the trial selection process is avail-
able in the appendix, http://links.lwu,.com/HIHlA24.
Included in this meca-analysis were available data from
randomized controlled trials comparing an antihyper-
tensive treatment to placebo or no treatfrent in patients
80 years and older u,ithin the follorving trials systolic
hypertension in the elderly program (SHEP)-Pilot [8],
SHEP [9], the European Working Party on High blood
pressure in the Elderly (EWPHE) [10], Coope and
Warrender [11], Swedish Trial in Old Patients (S:|OP)
[12], the Systolic Hypertension in Europe (Syst-Eur)
ll3l, HWET-Pilot [7] and HYVET [3]. The database
was already available for studies included in the subgroup
meta-analysis [1]. For the remaining studies [3,7] data
\vere extracted from the published papers. To our hnow-
ledge, these data represent all the available information
on mortality and morbidity related to the treatment of
hypertension versus placebo or no treatment in rando-
mized controlled trials in very elderly patients. The
cardiovascular study of the elderly (CASTEL) trial
[14], initially included in the subgroup meta-analysis
[1] was excluded because the trial compared two strat-
egies, 'special care'versus 'free therapy'.
Two other potential trials, the study on cognition and
prognosis in the elderly (SCOPE) [15] and the Japanese
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trial to assess optimal systolic blood pressure in elderly
hypertensive patients (JATOS) [16], were retrieved by
search in the Medline database using the following key-
words: blood pressure (BP) or hypertension, mortality,
over 80 and randomized controlled trial, with no language
restriction. These trials were excluded from the meta-
analysis because almost all control patients were treated
in the SCOPE trial and the JATOS trial compared two
active strategies, intensive versus mild.
Outcomes
In order to explore the observed heterogeneity between
earlier crials [1,7] and HWET [3], total mortality was
chosen as the primary outcome measure,
Secondary outcomes were coronary events, cardiovas-
cular events, stroke, heart failure and cause specific
mortality (coronary, stroke and cardiovascular).
Statistical analysis
The meta-analysis was based on aggregate data. The
subgroup meta-analysis and the two additional trials
[3,7] provided absolute number of events. RR and bilat-
eral95%CIs were calculated for every trial. The effect of
active tÍeatment versus placebo oÍ no treatment was
assessed using a random-effect model with measures of
between-trial variance and inconsistency between all
trials (tauz and i2). For trials that reported zero events
in one or both arms, a conrinuity correction using the
pseudo-count method was applied by adding 0.25 events
to all cells [17]. We also performed the meta-analysis of
the trials excluding HWET and assessed the heterogen-
eity between this subgroup of 'others' and HWET. A
P value of less than 0.10 was considered as significant for
the heterogeneity between groups test. The calculations
used EasyMA www.spc.univ-lyon1.fr/EasyMa and the
'meta' package from R software [18,19].
Three possible sources of heterogeneity between the
HWET and 'others' have been explored further as
the achieved BP reductions, the intensity of antihyper-
tensive therapy allowed in the trials and the changes of
treatment effect over time.
Intensity of antihypertensive therapy for each trial was
determined by giving a value of I for drugs given at the
recommended starting dose, 2 for twice the starting dose
and 3 for four times the starting dose. The same values
applied for second and thirtl-line drugs. The overall
intensity for each trial was the maximum dose of all
antihypertensive drugs allowed for that trial. For example
the HWET gets an intensity value of 2 because incla-
pamide was first-line at the recommended starting dose
and perindopril could be added at one-half the recom-
mended starting dose and increased to the recommended
starting dose as a maximum. The recommended starting
doses for hypertension treatment were taken from the
Physicians' Desk Reference, LISA. Linear fixed-effect
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meta-regression model with trial weights corresponding
to the inverse of the variance was perfoÍmed to explore
the relationship between the intensity of antihyperten-
sive therapy and the log-transformed value of the odds
ratios (ORs). We chose the log-transformed value of the
ORs because of its properties of symmetry around zero. A
similar model was used to explore the relationship
between SBP reductions (mean differences berween
active and control groups during follow-up) and rhe
log-transformed value of the ORs. Only trials, for which
information about BP reductions and total mortality out-
come was available, were included in this analysis
13,7,9,10,12,131. Random-effect Poisson model was used
to compute cumulative hazard ratio at the end of each
year of follow-up up to 5 years. Trials included in this
analysis were those for which individual patient dara
were already available in our database [8-12]. All
analyses were performed using the R software versron
2.10.1 n8l.
Results
Baseline characteristics of trials included in the meta-
analysis are summarized in Table 1. The analysis was
based on 6701 patients, ofwhom 3617 have been treated
with at least one antihypertensive drug (active gÍoup).
With the exception of two trials carried out in the United
States [8,9] and with the exception of HWET, all other
trials were performed in European countries U,10-13].
HWET trial recruited also patients from China, Austra-
lasia and Tunisia [3]. Nlean SBP at entry \vas 173 mmHg
in the H\I,/ET population and about 180 mmHg in rhe
remaining trials. The mean follow-up was 3.5 years in the
subgroup meta-analysis, 1.1 year in the HYVET pilot and
1.8 years in the HWET main. Percenrage of patients
with history of diabetes was lower, and previous stroke
and previous hypertension treatment were more frequent
in the HWET.
Primary outcome
The overall relative mortality risk was 1.06 (95%C10.89-
1,25, P:0.54) with significant heterogeneity IP:0.07,
tauz : 0.0236, Íz : CS.ZVo (0%-75.9%)1, confirming the
previous meta-analyses [4,5] (Fig. 1). Likewise, highly
statistically significant heterogeneity was observed
when comparing HYVET to the 'others' (P:0.003,
tau' : 0.0504 , I" = 88.8%). Between trials heterogeneiry
in the random-effect model disappeared when the results
from HWET were removed tP:0.79, tauz 
-0, F -0%(0%-44.4Vo)1.
Secondary outcomes
There was no heterogeneity between trials for secondary
endpoints in the random-effect meta-analysis (Fig. 2).
Furthermore, when comparing HWET with the 'others',
no heterogeneity was observed for coronary events(P:0,78, tauz :0.00, 12 :0%), stroke (P:0.43,
tau2:0.00, I2 :0%), cardiovascular events (P:0.64,
tauz :0.00, Í'z :O% heart failure (P:0.23, tau2 :0.03,
iz 
-32.3Vo), and cause-specific mortality: coronary death(P:0.70, tauz:0.00, 12 :0%), stroke dearh (P:0.21,
tauz:0.03, 12 :37.6Vo), except for cardiovascular ileath(P:0.06, tauz :0.04, tz :71.5%).
Antihypertensive therapy was associated with statistically
significant reduction in stroke (35%, P <0.001), cardio-
vascular events (27%, P < 0.001) and heart failure (50%,
P:0.001). On the contrary, coronary events and cause-
specific mortality weÍe not different between treated and
nontreated patients (Fig. 2). Considering a population
who would experience an annual incidence of l.\Vo for
stroke in untreated patients, as reported by the HWET,
the observed benefit on stroke prevention can be esti-
mated as an absolute risk reduction of 3Vo over 5 years,
meaning that one stroke is prevented for every 33
Datients treated for 5 vears.
Table 1 Baseline characteristics of trials (subgroups and full trials) involved in the meta-analysis
Subgroup meta-analysis (N 
- 
1 573) HYVET Pilot (/V- 1283) HYVET (/V= 3845)
5 double-blind and 1 open label Open label Double-blind
Nperarm Active (N:827) Control (N-746) Active (N-857) Control (N:426) Active (N- 1933) Conrrol (N:1912)
Population West-Europe (4 trials), United States (2 trials) East Europe (91 0/o) East Europe (560/0) + China (4oolo)
Active medication (Íirst line) Du or BBb or CA' D" or ACEId D.
l\4ean (SD) age (years) 83 (3) 83.8 (3) 80.6 (3.2)
Men/women (o/o) 3O/7O g7/65 40/60
Mean (SD) blood pressure (mmHg) 1 80/84 (1 3/8) 1 8211 oo (1 1 /3) 1 zgl9 1 (9/9)
Range SBP 160-232 160-217 160-j99
Range DBP <120 90-114 <1'lO
Curent smokers (o/o) ? 4,2 6.b
Diabetes (o/o) 14.0 NA 6.9
Previous Ml (o/o) 5.0 3.0 S, j
Previous stroke (o/o) 4.O 4.5 6.8
Previous HT treatment (0/o) 34' 4A 6b
Mean Íollow-up (range) 3.b (0-11.6)" 1,1 (NA) 2.1 (0-6.5)
HÏ, hypedension; NA, not available. a Diuretics: hydrochlorothiaide plus triamterene or amiloride in respectively EWPHE and STOP trials; chlorthalidone in SHEP-P and
SHEPtriaIS;bendroÍ|uazideinHYVET.Pilottrials;indapamideSRinHYVÊïtrials.bBeta"B|ockers:atenolo|intheCoopeandWarrender
enzyme inhibitors: lisinopril in HYVET Pilot trjal. "Value obtained without Syst-Eur, SHEP-Pilot and STOP trials.
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Fig. I
Total mortality
random effect model meta-analysis
sHEP 1991
sHPP 1989
SYST-EUR 1997
EWPHE 1987
sToP 1991
HYVET Pilot 2003
Coope 1986
HYVET 2OO8 23511912 0,83[0.69;0.99]
Random e{ïect model
1,06 [0.89; p.ass = 0.53
p.het = 0.07 t2 = 0.01 12 = 460/0l0%i76%1
0.1 0.2 0.5 1.0 2.0
Ïeatment better Relative risk Control better
Random-eÍÍect meta-analysis for total mortality. The figure provides number oí events, number of patients in treatment and control groups, relative
risks (RR) and 950/o confidence interval (Cl) for each trial, overall RR estimate with 950/o Cl and Pvalue for association test, Pvalue for heterogeneity
test, between trial variance (tau') and inconsistency (/') measures.
ïreatmenl
event/N
57/331
'10170
721231
58/70
111122
51 1857
0/3
196/1933
C ont rol
event/N
59is19
0/15
531210
60/85
8/1 13
221426
014
RR [e5% Cr]
0.93 [0.67; 1.30]
8090 [0.18;452.5]
1.24 [0.91t 1.67)
1.18 [0.99; 1.40]
1,27 [0.53; 3.05]
1.29 [0.80; 2.08]
1.31 [0.01;276.0]
5,0
Intensity of antihypertensive therapy and risk of death
The information regarding intensity of antihypertensive
therapy and risk of death was available for all eight trials.
Nevertheless, the subgroup of patients in Coope and
Warrender trial was not included in the analysis, as there
\l'ere no events observed in either group (Table 2). The
Fig. 2
linear meta-regression showed an inverse relationship
between the maximum treatment units allowed in each
trial and the benefit of treatment on total mortality
expressed as the log-transformed value of the OR
(slope : 0.2, standard erroÍ (SE) : 9.924, P < 0.01)
(Fie. 3).
Stroke
Cardiovascular events
Coronary events
Coronary death
Stroke death
Cardiovascular death
Secondary endpoints summary
random efÍect model
+
N trials
7
6
RR [e5% Cr]
0.05 [0.52;0.83]
0.73 [0.62; 0.80]
0.50 [0.33; 0.76]
0.83 [0.56; 1.22]
0.99 [0.69; 1 .a1]
0.80 [0.80;1.11]
0.98 [0.83; 1.15]
p.ass p.neT
<0.00'1 0.44
<0.001 0.78
0.001 0.28
0.33 0.80
0.95 0.93
0.17 0.53
0.78 0.46
t2 tgs"/, ctl Í2
0oÁ10%;70%) 0.00
0o^Í0%;49%l 0.00
21%10%i65%1 0.05
A%[0oÁ;33oÁl 0.00
0% [0%;90Á] 0.00
0%[0%;63%1 0.00
0%[0%;66%] 0.00
HeartÍailure + 6
6
0.2 0.4 0.6 0.8 1 .0 1.2 1 .4
Treatment better Relative risk Control better
Secondary endpoints estimates from random-effect meta-analysis. The Íigure provides number oÍ trials used for each endpoint meta-analysis,
common relative risk (RR) estimates from random-effect model with 950/o confidence interval (Cl), P value for association test, P value íor
heterogeneity test, between-trial variance (tau2) and inconsistency (/2) measures.
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SHEP
SHEP-Pilot
Syst-Eur
EWPHE
STOP
HYVËT-Pilot
HWET
Total'
1 1 mmHg
NA
1 2 mmHg
1 7 mmHg
1 I mmHg
23 mmHg
'12 mmHg
1 4 mmHg
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Table 2 Intensity oÍ antihypertensive therapy expÍessed as
maximum treatments units and mean SBP reductions in the
included trials
Maximum treatment units Mean SBP reduction
Fig. 4
Total mortality
23
Time (years)
Cumulative hazard ratio (black squares) and 950/o Cl up to 5 years from
random-effect Poisson model and extrapolated point estimate (black
dots) hazard ratio for the HYVET.
Discussion
Consistent with the finding of the pÍevious subgroup
meta-analysis and the HWET, the resr-rlts of this
meta-analysis indicate significant reduction in the rates
of stroke, heart failure and cardiovascular events ln
patients treated with antihypeÍtensive drugs as compared
with placebo or no treatment. On the contrary, ollr results
do not support those of the HWET with regard to the
3
5
5
6
J.C
4
2
3
|,o
;
- 1^E'
6
s 1.2
o
6
= 
1.0
E
f
0.8
L
NA, not available. 'Average maimum treatment units and mean SBP reduction
were obtained after weighting by trial size,
Mean difÍerences in SBP during follow-up and risk of
death
Mean differences in SBP during the follow-up period
were available for six trials [3,7,9,10,12,13], ranging
from 10.8mmHg (SHEP) to 23mmHg (HWET-pilot).
The linear meta-reÉ{ression showed an inverse relation-
ship betu,een the extent of SBP reduction and benefits
of treatment on total mortality expressed as the log-
transformed value of the OR (slope :0.04, SE :0.029,
P:0"23) (Fig. 3).
Changes of treatment efÍect over time
The cumulative hazard ratio of total mortality over time
in five rrials [8*12] displayed a significant deleterious
effect at the end of the third year [hazard ratio:1.35
(1.08-1.70)l and reached a nonsignificanthazard ratio of
1.17 (0.93-1.47) ar. 5 years (Fig. a). The relative risk
extrapolated from the Kaplan-Meyer curves of the
HWET [3] showed a different pattern of treatment
effect over time, reinforcing the contrast between the
HWET and other trials.
Fig. 3
(b)(a)
3.0
2.5
o 
.^
.9
;! 10
Total mortality and SBP reductions
10 15 20 25
SBP reductions in each trial
3.0
2.5
ïotal mortality and intensity oÍ
anti hypertensive treatment
23450
Maximum treatment units in each trial
o ^^G Z,U
O
a
o
o rr
= 
,.u
.9
6
a
^
Linear meta-regression between the log transformed value of total morlality odds-ratio (OR) and: a 
- 
the mean SBP reductions; b 
- 
the intensity of
antihyperlensive therapy (maximum treatment units).
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reduction, in the treated group, of death from all-cause
mortality.
Methodological aspects, the study population, type and
dose ofantihypertensive therapy and the achieved differ-
ences in BP between groups could explain the observed
discrepancy in the effect of antihypertensive therapy on
total mortality.
The methodological strength of the HWET due to its
double-blind character could explain the observed
heterogeneity. However, this is unlikely because limiting
the analysis to double-blind trials involved in the sub-
group meta-analysis displayed an even higher RR of 1.14(P:0.05).
Larger-than-expected treatment effect may result from
analyzing data at a 'random-high', that is simply by
chance when stopping randomized trials early because
of an apparent benefit [20]. This should be remembered
r'vhen making inferences to clinical practice from trun-
catecl trials. HWET and STOP (full trial) are the only
two crials that for.rnd a significanr benefit on total
mortalicy and were both stopped earlier then planned
[3,12]. Time-trend analysis of treatment effect showed a
steady effect over time in the HWET, contrasting with
the deleterious effect observed in other trials (Fig. 4).
The differences in follow-up durations aÍe, therefore, not
likely to explain the observed heterogeneity with regard
to total mortality.
More than one-third of the HWET population was
recruited in China. The baseline characteristics of this
subgroup were recently compared u'ith the rest of the
study p<-rpulation [21]. The results shorved that Chinese
patients had significantly lower BNII, lower sitting DBP,
lower total cholesterol, higher high-density lipoprotein(HDL) cholesterol and better renal function. Further-
more, previous episodes of myocardial infarccion and
congestive-heaÍt failure were significantly lower among
Chinese. However, better health condition of this popu-
lation at study entry could hardly explain the benefit of
antihypertensive treatment on total mortality. Indeed the
estimated annual mortality rate in control groups varied
from 3.4 llZl to 1511% [10], HWET being somewhere in
the rniddle at approximately 6%.
The long-acting thiazide diuretics, chlorthalidone [22]
and indapamide SR were used as first-line therapy in the
tu,o trials that reported decrease in total mortality in
treated patients [3,9]. This observation suÉigests that
these drugs rnay provide beneficial effects on total
mortality. However, first-line thiazides were also used
in a substantial proportion of patients in four of the other
six trials, so this alone does not explain the heterogeneity.
The exploratory meta-regressions suggest possible associ-
ation between the increase in total mortality and higher
intensity of antihypertensive treatment. Similar associ-
ation was observed between the increase in total mortalitv
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and the achievecl SBP reductions. Both the intensity of
antihypertensive treatment ancl the achieved SBP redr-rc-
tion represent a common motivation to further control BP.
In the recent JATOS trial including patients 65-8.5 years
old, the strict BP control did not provide further benefit in
risk reduction as compared with the mild-BP control.
Overall, 54 patients died in the strict BP arm versus 42
in the mild-BP arm. Even though not statistically signifi-
cant (P: 0.ZZ), this result suggests a deleterious effect of
intensive-BP control in elderly [16] in keeping with our
findings. The results are compelling enough to recom-
mend a low-maximal intensity of antihypertensive therapy
in individuals 80 years and over. It also suggests that other
trials need to be carried out to determine whether there is a
deleterious effect of more intensive-antihypertensive
therapy in younger age groups as well.
In conclusion, particular attention should be given to
hypertensive elderly patients who constitute a large,
growing and vulnerable population. Treating hyperten-
sion in very old patients reduces stroke and heart failure,
Despite this, the meta-analysis of the best available
evidence showed no decrease in total mortality and the
mortality results were heterogeneous. The heterogeneity
was best explained by an increase in mortality in trials
where the maximal allowable antihypertensive treatment
and BP lowering were greater, although our results are not
robust enough to definitively conclude that over treat-
ment and excessive blocld pressure lou,ering increase
mortality. In patients over 80 years old the most reason-
able strategy is the one proposed by the HWET trial: a
thiazide diuretic as first-line therapy and a maximalanti-
hypertensive therapy with two drugs in low doses.
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